Kunming, China – 07 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center has published the changes in drug attributes for online trading, covering 37 product entries realigned with the National Essential Drug List (2026 Edition), and announced that notification‑commitment filing (告知承诺备案) for essential‑drug status takes effect immediately for all listed products attributed as “Essential Drug (including former provincial supplement).”
Procurement Milestone
| Item | Detail |
|---|---|
| Issuing Authority | Yunnan Provincial Government Procurement and Transfer Center |
| Notice Type | Public disclosure of drug attribute changes (online trading platform) |
| Policy Basis | National Essential Drug List (2026 Edition) |
| Scope | 37 product entries across injectables, inhalation solutions, oral solids, TCM preparations and topical dosage forms |
| Disclosure Date | 7 Sep 2026 |
| Key Constants | Approval numbers unchanged; procurement ceiling prices unchanged for all entries |
| Filing Requirement | Notification‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) — effective immediately |
| Objection Window | 5 business days from the disclosure date |
Attribute Changes at a Glance
| Category | Entries | Representative Products | Change |
|---|---|---|---|
| Essential‑drug status retained | 32 | Esomeprazole sodium for injection, ambroxol injection, milrinone injection, somatostatin for injection, nintedanib esylate soft capsules, cilostazol tablets, edaravone–dexborneol injection, ipratropium bromide inhalation solution (7 entries), azithromycin dry suspension | Essential drug → Essential drug (2026 List) |
| Upgraded to essential drug | 3 | Dalteparin sodium injection; nadroparin calcium injection (2 specs) — Yantai Dongcheng Northern Pharmaceutical | Non‑essential → Essential drug |
| Reclassified to former provincial supplement | 2 | Dengzhanxixin granules — Yunnan Plant Pharmaceutical | Essential drug → Former provincial supplement (原省补) |
- Manufacturer Footprint: The batch spans roughly 20 producers, including Langtian Pharmaceutical (Hubei) (9 entries), Simcere Pharmaceutical, Chengdu Beit, Shaanxi Hanwang, and France‑based Laboratoire Unither, whose ipratropium bromide solution is bid through Sinopharm Distribution Center — evidence of continued import participation in Yunnan’s platform.
Essential Drug Filing Obligation
- Who Must Act: All enterprises whose products carry the “Essential Drug (including former provincial supplement)” attribute in the disclosure.
- Procedure: Complete the notification‑commitment filing per the Yunnan Provincial MPA’s published requirements, bringing a printed copy of this announcement to the designated filing site.
- Filing Site: Reception Hall, 1st Floor, Yunnan Institute for Food and Drug Control (new building, 616 Kefa Road, Kunming); filing hotline 0871‑63112057.
- Compliance Warning: Enterprises that fail to complete the filing bear the consequences — a clear signal that unfiled products risk losing essential‑drug procurement privileges on the platform.
Objection & Public Supervision
- Applicant Enterprises: Queries on the disclosed information must be raised within 5 business days to the Center’s Drug & Device Procurement Section (0871‑63606934).
- General Public & Third Parties: Objections to the disclosure are accepted within 5 business days by the Comprehensive Supervision Section (0871‑65330065), keeping the process open to public scrutiny.
Market Impact & Outlook
- 2026 List Alignment: This batch operationalizes the National Essential Drug List (2026 Edition) at the provincial trading level, with price ceilings and approval numbers held steady — suppliers gain attribute certainty without repricing risk.
- Anticoagulant Upgrade: The promotion of dalteparin and nadroparin from non‑essential to essential status strengthens the procurement position of Yantai Dongcheng Northern Pharmaceutical in Yunnan’s public‑hospital channel.
- TCM Reclassification: Moving dengzhanxixin granules to the “former provincial supplement” track preserves preferential treatment for legacy provincial items even after national‑list streamlining.
- Filing as Gatekeeper: The immediate‑effect notification‑commitment regime makes filing a de facto compliance checkpoint — enterprises should treat it as a short‑fuse administrative deadline tied directly to continued listing.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing completion, objection outcomes, and procurement treatment of the disclosed products. Actual results may differ due to risks including filing verification, third‑party objections, and subsequent announcements by the Yunnan Provincial MPA and the Center.-China Health Reform Pulse
Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27813&CatalogId=3